EGFR and glioblastoma: Dacomitinib did impair the growth of tumors containing EGFR amplification in GBM xenograft models,56 but only showed limited activity in clinical trials with recurrent GBM containing EGFR amplification (NCT01520870).28 This study found no significant improvement of PFS-6, regardless of EGFRvIII status.